Cross-HLA Targeting of Synthetic Neoepitopes with T-Cell Engagers to Eradicate KRASG12C Inhibitor-Resistant Cancers
Time: 3:30 pm
day: Day 1
Details:
• Development of high-specificity and high-affinity T-cell engaging bispecific antibodies (HapImmune antibodies) targeting KRASG12C inhibitor-modified HLA peptides (haptenpeptides, “p*MHCs”)
• Direct detection of p*MHCs by mass spectrometry, detailed target characterization, and demonstrated in vitro/in vivo activity of HapImmune antibodies
• Demonstration of the molecular-basis for cross-HLA recognition, examples spanning alleles within and across HLA supertypes
